The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Evaluating surrogacy endpoints in CLL clinical trials
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses a meta-analysis evaluating various surrogacy endpoints in chronic lymphocytic leukemia (CLL) clinical trials, including progression-free survival (PFS) and undetectable measurable residual disease (MRD) rates. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, Roche, AbbVie, BeiGene, AstraZeneca: Research Funding;
Janssen, Roche, AbbVie, BeiGene, AstraZeneca, MSD: Speakers Bureau;
Beigene: Other: Travel Support;
Janssen, AbbVie, Lilly, AstraZeneca, BeiGene, MSD: Consultancy.
